Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. Pfizer’s proposed combination with Allergan creates a global R&D leader and will enable us to pursue cures and treatments for conditions ranging from Alzheimer’s and Parkinson’s disease to cancer and rare genetic disorders.
The combination will allow us to invest a combined $9 billion in research and development, the bulk of it here in the U.S., making us one of the largest single R&D investors in America and expanding our ability to invest in the U.S.
Read Full Article »